zura bio is a clinical-stage biotechnology company advancing zb-168 in alopecia areata and other inflammatory diseases. zb-168 is an anti il7rα inhibitor that has the potential to impact diseases driven by il7 and tslp biological pathways. zura bio aims to develop a portfolio of therapeutic indications for zb-168, and is focused on demonstrating its efficacy, safety, dosing convenience and mechanism of action, initially in alopecia areata. this will build on phase 1b data in type 1 diabetes demonstrating a favourable safety profile and strong biological rationale. zura bio is headquartered in london, uk with team members in the uk and usa.
Company profile
Ticker
ZURA, ZURAW
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
JATT Acquisition Corp
SEC CIK
ZURA stock data
Latest filings (excl ownership)
8-K
Zura Bio Announces Robert Lisicki as CEO and Director
8 Apr 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer
28 Mar 24
8-K
Regulation FD Disclosure
11 Mar 24
8-K
Zura Bio Announces Participation at March Conferences
4 Mar 24
8-K
Changes in Registrant's Certifying Accountant
23 Feb 24
8-K
Zura Bio Announces Participation at February Investor Conferences
2 Feb 24
8-K
Regulation FD Disclosure
11 Jan 24
8-K
Zura Bio Continues to Strengthen Leadership with Appointment of Robert Lisicki as President and Kiran Nistala as CMO
8 Jan 24
8-K
Zura Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Dermatology Summit
3 Jan 24
Latest ownership filings
SC 13G/A
GREAT POINT PARTNERS LLC
14 Feb 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
SC 13G/A
ACCESS INDUSTRIES MANAGEMENT, LLC
14 Feb 24
SC 13G/A
GLAZER CAPITAL, LLC
13 Feb 24
SC 13G/A
Alberta Investment Management Corp
12 Feb 24
SC 13G/A
Hudson Bay Capital Management LP
6 Feb 24
4
Robert Lisicki
26 Jan 24
4
van Amstel Arnout Ploos
26 Jan 24
4
Parvinder Thiara
26 Jan 24
4
Kiran Nistala
26 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 103.86 mm | 103.86 mm | 103.86 mm | 103.86 mm | 103.86 mm | 103.86 mm |
Cash burn (monthly) | 2.98 mm | (no burn) | 3.40 mm | 5.96 mm | 39.67 k | 346.95 k |
Cash used (since last report) | 19.88 mm | n/a | 22.65 mm | 39.74 mm | 264.60 k | 2.31 mm |
Cash remaining | 83.97 mm | n/a | 81.21 mm | 64.12 mm | 103.59 mm | 101.54 mm |
Runway (months of cash) | 28.2 | n/a | 23.9 | 10.8 | 2611.6 | 292.7 |
Institutional ownership, Q3 2023
66.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 45 |
Opened positions | 7 |
Closed positions | 4 |
Increased positions | 21 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 93.24 bn |
Total shares | 28.91 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Hana Immunotherapeutics | 5.40 mm | $0.00 |
Ewon Comfortech | 3.65 mm | $0.00 |
Great Point Partners | 3.30 mm | $21.75 bn |
PFE Pfizer | 2.97 mm | $0.00 |
Suvretta Capital Management | 2.85 mm | $18.81 bn |
JATT Ventures | 2.74 mm | $0.00 |
Deep Track Capital | 2.52 mm | $16.65 bn |
Armistice Capital | 1.58 mm | $10.43 bn |
Citadel Advisors | 712.50 k | $4.70 bn |
BLK Blackrock | 579.50 k | $3.82 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
24 Jan 24 | Robert Lisicki | Stock options Class A Ordinary Shares | Grant | Acquire A | No | No | 3.98 | 1,000,000 | 3.98 mm | 1,000,000 |
24 Jan 24 | van Amstel Arnout Ploos | Stock options Class A Ordinary Shares | Grant | Acquire A | No | No | 3.98 | 48,149 | 191.63 k | 48,149 |
24 Jan 24 | Parvinder Thiara | Stock options Class A Ordinary Shares | Grant | Acquire A | No | No | 3.98 | 48,149 | 191.63 k | 48,149 |
24 Jan 24 | Kiran Nistala | Stock options Class A Ordinary Shares | Grant | Acquire A | No | No | 3.98 | 350,000 | 1.39 mm | 350,000 |
News
Zura Bio Announces Oversubscribed $112.5M Private Placement For 20.1M Class A Shares At A Price Of $3.108 Per Share; Financing Includes New And Existing Leading Life Sciences Institutional Investors; Strengthened Balance Sheet Expected To Fund Operations Through 2027
18 Apr 24
Zura Bio Announces That Robert Lisicki Has Assumed The Role Of Chief Executive Officer And A Director
8 Apr 24
Oppenheimer Reiterates Outperform on Zura Bio, Lowers Price Target to $16
1 Apr 24
Zura Bio Q4 EPS $(0.30) Misses $(0.23) Estimate
28 Mar 24
12 Health Care Stocks Moving In Friday's Intraday Session
22 Mar 24
Press releases
Zura Bio Announces Oversubscribed $112.5 Million Private Placement
18 Apr 24
Zura Bio Announces Robert Lisicki as CEO and Director
8 Apr 24
Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer
28 Mar 24
Zura Bio Announces Participation at March Conferences
4 Mar 24
Zura Bio Announces Participation at February Investor Conferences
2 Feb 24